Use of health services by prison inmates

Comparisons with the community: Table 1

Bibliographic Data

ID11173644
AuthorsTom Marshall (0000-0001-9277-5214, University of Birmingham, corresponding author), S Simpson (University of Birmingham), A Stevens (0000-0002-3905-022X, University of Birmingham)
Year2001
Volume55
Issue5
Pages364-365
Publication date2001-05-01
Open AccessNo
TypeARTICLE
VenueJournal of Epidemiology and Community Health (JOURNAL)
Journal identifiersISSN: 0143-005X • E-ISSN: 1470-2738
PublisherBMJ (PUBLISHER • GB)
DOI10.1136/jech.55.5.364
PMID11297662
OpenAlexW2003404720
LanguageEN
Citations received18

Vaccines targeting SARS-CoV-2 have gained emergency FDA approval, however the breadth against emerging variants and the longevity of protection remains unknown. Post-immunization boosting may be required, perhaps on an annual basis if the virus becomes an endemic pathogen. Seasonal influenza virus vaccines are already developed every year, an undertaking made possible by a robust global vaccine production and distribution infrastructure. To create a seasonal combination vaccine targeting influenza viruses and SARS-CoV-2 that is also amenable to frequent reformulation, we have developed a recombinant influenza A virus (IAV) genetic platform that “reprograms” the virus to package an immunogenic domain of the SARS-CoV-2 spike (S) protein onto IAV particles. Vaccination with this combination vaccine elicits neutralizing antibodies and provides protection from lethal challenge with both pathogens. This technology may allow for leveraging of established influenza vaccine infrastructure to generate a cost-effective and scalable seasonal vaccine solution for both influenza and coronaviruses

Criminology · Prison · Psychiatry · Influenza Virus Research Studies · Medicine · SARS-CoV-2 and COVID-19 Research · Viral Infections and Outbreaks Research · Gerontology

Tools

Open DOISci-HubOpen Access